



uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2023

LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- [uniQure N.V.](#) (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees.

The Company granted equity awards to 42 employees as a material inducement to commencing their employment. In the aggregate, those employees received 98,900 restricted share units and options to purchase 90,500 ordinary shares of the Company. Each option has an exercise price of \$6.90 per share, the closing price per ordinary share as reported by Nasdaq on September 27, 2023 (the "Grant Date"). Each option has a ten-year term and will vest over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters thereafter. The restricted share units vest in three approximately equal annual installments beginning on September 27, 2024.

The aforementioned equity awards were approved by the Company's board of directors on September 27, 2023 and were issued to newly hired employees as a material inducement to commencing their employment with the Company in accordance with and under Nasdaq Listing Rule 5635(c)(4).

About uniQure

uniQure's mission is to reimagine the future of medicine by delivering innovative cures that transform lives. The recent approvals of our gene therapy for hemophilia B – a historic achievement based on more than a decade of research and clinical development – represents a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology and manufacturing platform to advance a [pipeline](#) of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory mesial temporal lobe epilepsy, amyotrophic lateral sclerosis (ALS), Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:

Chiara Russo

Direct: 617-306-9137

Mobile: 617-306-9137

c.russo@uniQure.com

FOR MEDIA:

Tom Malone

Direct: 339-970-7558

Mobile: 339-223-8541

t.malone@uniQure.com

